PURPOSE: The identification of subjects with systemic sarcoidosis at higher risk for sudden death is an unresolved issue. An influence of the autonomic activity on the genesis of ventricular arrhythmias was postulated. Heart rate variability (HRV) analysis provides a useful method to measure autonomic activity, and is a predictor of increased risk of death in various conditions. Therefore, the aim of the study was to evaluate HRV in patients with systemic sarcoidosis. METHODS: The study included 35 patients with biopsy proven systemic sarcoidosis who were not taking antiarrhythmic medications. Thallium scintigraphy was performed to all patients with systemic sarcoidosis. The cardiac sarcoidosis was accepted in 16 patients as abnormal thallium scintigraphy and normal coronary arteriography. The time-domain analysis of HRV was expressed as the standard deviation of all normal to normal NN intervals (SDNN) detected during 24-hour Holter monitoring. Twenty-four healthy subjects represented a control group for HRV analysis. RESULTS: There were no differences in age (44 +/- 13 years for cardiac sarcoidosis, 42 +/- 15 years for noncardiac sarcoidosis, and 40 +/- 10 years for control group; P = NS), sex (the ratio of female; 63%, 68%, and 55%, respectively; P = NS), and echocardiographic ejection fraction (63 +/- 10%, 67 +/- 8%, and 69 +/- 6%, respectively; P = NS) among study groups. The mean SDNN value of the group with cardiac sarcoidosis was significantly lower than both the group with noncardiac sarcoidosis and the control group (72 +/- 32 ms vs 110 +/- 46 ms and 152 +/- 36 ms; P < 0.05, respectively). CONCLUSION: HRV is decreased in patients with systemic sarcoidosis compared to the control group. This decreasing is more obvious in patients with cardiac sarcoidosis.
PURPOSE: The identification of subjects with systemic sarcoidosis at higher risk for sudden death is an unresolved issue. An influence of the autonomic activity on the genesis of ventricular arrhythmias was postulated. Heart rate variability (HRV) analysis provides a useful method to measure autonomic activity, and is a predictor of increased risk of death in various conditions. Therefore, the aim of the study was to evaluate HRV in patients with systemic sarcoidosis. METHODS: The study included 35 patients with biopsy proven systemic sarcoidosis who were not taking antiarrhythmic medications. Thallium scintigraphy was performed to all patients with systemic sarcoidosis. The cardiac sarcoidosis was accepted in 16 patients as abnormal thallium scintigraphy and normal coronary arteriography. The time-domain analysis of HRV was expressed as the standard deviation of all normal to normal NN intervals (SDNN) detected during 24-hour Holter monitoring. Twenty-four healthy subjects represented a control group for HRV analysis. RESULTS: There were no differences in age (44 +/- 13 years for cardiac sarcoidosis, 42 +/- 15 years for noncardiac sarcoidosis, and 40 +/- 10 years for control group; P = NS), sex (the ratio of female; 63%, 68%, and 55%, respectively; P = NS), and echocardiographic ejection fraction (63 +/- 10%, 67 +/- 8%, and 69 +/- 6%, respectively; P = NS) among study groups. The mean SDNN value of the group with cardiac sarcoidosis was significantly lower than both the group with noncardiac sarcoidosis and the control group (72 +/- 32 ms vs 110 +/- 46 ms and 152 +/- 36 ms; P < 0.05, respectively). CONCLUSION: HRV is decreased in patients with systemic sarcoidosis compared to the control group. This decreasing is more obvious in patients with cardiac sarcoidosis.
Authors: R E Kleiger; J T Bigger; M S Bosner; M K Chung; J R Cook; L M Rolnitzky; R Steinman; J L Fleiss Journal: Am J Cardiol Date: 1991-09-01 Impact factor: 2.778
Authors: H V Huikuri; T Mäkikallio; K E Airaksinen; R Mitrani; A Castellanos; R J Myerburg Journal: J Am Coll Cardiol Date: 1999-12 Impact factor: 24.094
Authors: Y Matsui; K Iwai; T Tachibana; T Fruie; N Shigematsu; T Izumi; A H Homma; R Mikami; O Hongo; Y Hiraga; M Yamamoto Journal: Ann N Y Acad Sci Date: 1976 Impact factor: 5.691
Authors: J I Gamez-Nava; L Gonzalez-Lopez; C Ramos-Remus; M M Fonseca-Gomez; E G Cardona-Muñoz; M E Suarez-Almazor Journal: J Rheumatol Date: 1998-06 Impact factor: 4.666
Authors: Z Aktop; H Tanrıverdi; F Uygur; A İşleyen; B Kalaycı; Y C Gursoy; T Karabağ; M Aydın; I Akpınar Journal: Herz Date: 2016-10-13 Impact factor: 1.443
Authors: Jefferson Curimbaba; João Pimenta; José Marcos Moreira; UlSilvia Carla Sousa Rodrigues; Ester Nei Aparecida Coletta; Carlos A C Pereira Journal: J Atr Fibrillation Date: 2012-12-16